{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:41:59Z","timestamp":1791574919940,"version":"4.3.4"},"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Patients with rheumatoid arthritis (RA) who receive immunosuppressive medications have a heightened risk of infection. The goal of our study was to calculate the pooled cumulative incidence and risk of infection in patients with RA treated with Janus kinase inhibitors (JAKi). The PubMed and EMBASE databases were queried for randomized controlled trials comparing patients with RA treated with JAKi (upadacitinib, baricitinib, tofacitinib, peficitinib, or filgotinib), defined as the treatment group, compared with control subjects, defined as participants receiving placebo or treatment regimen that was similar to that of participants in the treatment group, with the exception of JAKi. The primary study endpoint was the relative risk (RR) of any-grade and severe infection. The secondary endpoints were RR and cumulative incidence of opportunistic infections, herpes zoster, and pneumonia. The Stata v17 software was used for all data analysis. Results showed that treatment with baricitinib was associated with an increased risk of any-grade (RR 1.34; 95% CI: 1.19\u20131.52) and opportunistic (RR 2.69; 95% CI: 1.22\u20135.94) infection, whereas treatment with filgotinib (RR 1.21; 95% CI: 1.05\u20131.39), peficitinib (RR 1.40; 95% CI: 1.05\u20131.86) and upadacitinib (RR 1.30; 95% CI: 1.09\u20131.56) was associated with increased risk of any-grade infection only. Analysis based on type of infection showed a pooled cumulative incidence of 32.44% for any-grade infections, 2.02% for severe infections, 1.74% for opportunistic infections, 1.56% for herpes zoster, and 0.49% for pneumonia in patients treated with any JAKi during the follow-up period. Treatment with specific JAKi in patients with RA is associated with an increased risk of any-grade and opportunistic infections but not severe infection. Close clinical monitoring of patients with RA treated with JAKi is required to establish the long-term infection risk profile of these agents.<\/jats:p>","DOI":"10.1371\/journal.pone.0306548","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:48:20Z","timestamp":1722455300000},"page":"e0306548","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"given":"Konstantinos","family":"Ouranos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia K.","family":"Mylona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanos","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Shehadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-0777","authenticated-orcid":true,"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"pone.0306548.ref001","doi-asserted-by":"crossref","first-page":"vi12","DOI":"10.1093\/rheumatology\/keab609","article-title":"Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs","volume":"60","author":"Y. Tanaka","year":"2021","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0306548.ref002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"JS Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref003","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"L Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"pone.0306548.ref004","doi-asserted-by":"crossref","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","article-title":"The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.","volume":"12","author":"S Shams","year":"2021","journal-title":"Front Pharmacol."},{"key":"pone.0306548.ref005","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.","volume":"10","author":"J Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"pone.0306548.ref006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.","volume":"52","author":"J Listing","year":"2013","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0306548.ref007","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"PA Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"pone.0306548.ref008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.","volume":"18","author":"Y Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"pone.0306548.ref009","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"key":"pone.0306548.ref010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"pone.0306548.ref011","first-page":"vi5","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria.","volume":"51","author":"J Kay","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0306548.ref012","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"KL Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref013","unstructured":"National Cancer Institute\u2019s Common Terminology Criteria for Adverse Events (CTCAE). Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"pone.0306548.ref014","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0306548.ref015","unstructured":"The Handbook of Research Synthesis and Meta-analysis. Available from: https:\/\/www.daneshnamehicsa.ir\/userfiles\/files\/1\/9-%20The%20Handbook%20of%20Research%20Synthesis%20and%20Meta-Analysis.pdf."},{"key":"pone.0306548.ref016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"pone.0306548.ref017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data.","volume":"72","author":"VN Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"pone.0306548.ref018","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Stat Med"},{"key":"pone.0306548.ref019","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"JL Peters","year":"2006","journal-title":"JAMA"},{"key":"pone.0306548.ref020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1536867X0800800403","article-title":"Meta-Regression in Stata.","volume":"8","author":"RM Harbord","year":"2008","journal-title":"The Stata Journal"},{"key":"pone.0306548.ref021","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2665-9913(22)00092-3","article-title":"Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.","volume":"4","author":"R Fleischmann","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"pone.0306548.ref022","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"GR Burmester","year":"2018","journal-title":"Lancet"},{"key":"pone.0306548.ref023","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study.","volume":"59","author":"H Kameda","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0306548.ref024","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.","volume":"68","author":"JM Kremer","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"pone.0306548.ref025","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.","volume":"68","author":"MC Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"pone.0306548.ref026","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.","volume":"391","author":"MC Genovese","year":"2018","journal-title":"Lancet"},{"key":"pone.0306548.ref027","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/1756-185X.14235","article-title":"Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.","volume":"24","author":"X Zeng","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"pone.0306548.ref028","first-page":"991","article-title":"SAT0257\u2005A phase 2b\/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective jak1 inhibitor, in japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic dmards","volume":"77","author":"Y Tanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref029","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"M Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.","volume":"69","author":"R Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"pone.0306548.ref031","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24\u2005weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"EC Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref032","first-page":"732","article-title":"Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study","volume":"38","author":"Z Li","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"pone.0306548.ref033","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in Patients with Refractory Rheumatoid Arthritis","volume":"374","author":"MC Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"pone.0306548.ref034","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"PC Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0306548.ref035","first-page":"504","article-title":"Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind","volume":"43","author":"Y Tanaka","year":"2016","journal-title":"Randomized Placebo-controlled Study. J Rheumatol"},{"key":"pone.0306548.ref036","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"B Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref037","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.","volume":"322","author":"MC Genovese","year":"2020","journal-title":"JAMA"},{"key":"pone.0306548.ref038","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"R Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref039","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).","volume":"76","author":"R Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref040","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).","volume":"76","author":"A Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref041","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"DL Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref042","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.","volume":"381","author":"GR Burmester","year":"2013","journal-title":"Lancet"},{"key":"pone.0306548.ref043","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.","volume":"65","author":"D van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"pone.0306548.ref044","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","article-title":"Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.","volume":"17","author":"JM Kremer","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"pone.0306548.ref045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"J Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"pone.0306548.ref046","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"JM Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"pone.0306548.ref047","doi-asserted-by":"crossref","first-page":"e001040","DOI":"10.1136\/rmdopen-2019-001040","article-title":"Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial.","volume":"5","author":"V Strand","year":"2019","journal-title":"RMD Open"},{"key":"pone.0306548.ref048","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.","volume":"63","author":"Y Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"pone.0306548.ref049","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.","volume":"25","author":"Y Tanaka","year":"2015","journal-title":"Mod Rheumatol."},{"key":"pone.0306548.ref050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"RF van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0306548.ref051","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.","volume":"69","author":"AJ Kivitz","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"pone.0306548.ref052","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.","volume":"75","author":"T Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref053","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.","volume":"78","author":"T Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref054","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).","volume":"78","author":"Y Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref055","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.","volume":"69","author":"MC Genovese","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"pone.0306548.ref056","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"JS Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref057","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"MA Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"pone.0306548.ref058","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease.","volume":"13","author":"KL Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"pone.0306548.ref059","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.","volume":"58","author":"K Bechman","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0306548.ref060","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials","volume":"76","author":"SB Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref061","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"SB Cohen","year":"2020","journal-title":"RMD Open"},{"key":"pone.0306548.ref062","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"J Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"pone.0306548.ref063","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"PC Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref064","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41598-017-07261-1","article-title":"A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.","volume":"7","author":"Y Chen","year":"2017","journal-title":"Sci Rep"},{"key":"pone.0306548.ref065","doi-asserted-by":"crossref","first-page":"12792","DOI":"10.3390\/ijms241612792","article-title":"Simultaneous Assessment of mTORC1, JAK\/STAT, and NLRP3 Inflammasome Activation Pathways in Patients with Sarcoidosis.","volume":"24","author":"R Kraaijvanger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"pone.0306548.ref066","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12964-023-01240-y","article-title":"Double-edged sword of JAK\/STAT signaling pathway in viral infections: novel insights into virotherapy","volume":"21","author":"M Mahjoor","year":"2023","journal-title":"Cell Commun Signal"},{"key":"pone.0306548.ref067","doi-asserted-by":"crossref","first-page":"152120","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review","volume":"58","author":"K Winthrop","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"pone.0306548.ref068","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"KL Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref069","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"KL W Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref070","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.3390\/jcm11154459","article-title":"Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis.","volume":"11","author":"F Wang","year":"2022","journal-title":"J Clin Med."},{"key":"pone.0306548.ref071","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"KL Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"pone.0306548.ref072","doi-asserted-by":"crossref","first-page":"1759720X20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster.","volume":"12","author":"F Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"pone.0306548.ref073","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis.","volume":"14","author":"Q Xu","year":"2023","journal-title":"Front Pharmacol."},{"key":"pone.0306548.ref074","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jmoldx.2020.10.003","article-title":"Development and Evaluation of a Fully Automated Molecular Assay Targeting the Mitochondrial Small Subunit rRNA Gene for the Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid Specimens","volume":"22","author":"B Liu","year":"2020","journal-title":"J Mol Diagn"},{"key":"pone.0306548.ref075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.fgb.2014.10.003","article-title":"Cryptococcosis diagnosis and treatment: What do we know now","volume":"78","author":"JR Perfect","year":"2015","journal-title":"Fungal Genet Biol"},{"key":"pone.0306548.ref076","doi-asserted-by":"crossref","first-page":"210149","DOI":"10.1183\/20734735.0149-2021","article-title":"New developments in tuberculosis diagnosis and treatment","volume":"18","author":"CM Gill","year":"2022","journal-title":"Breathe (Sheff)."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:49:14Z","timestamp":1722455354000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306548"}},"subtitle":[],"editor":[{"given":"Benjamin M.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":76,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0306548","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}